Literature DB >> 22763238

Hypoxia is a modifier of SMN2 splicing and disease severity in a severe SMA mouse model.

Thomas W Bebee1, Catherine E Dominguez, Somayeh Samadzadeh-Tarighat, Kristi L Akehurst, Dawn S Chandler.   

Abstract

Spinal muscular atrophy (SMA) is a progressive neurodegenerative disease associated with low levels of the essential survival motor neuron (SMN) protein. Reduced levels of SMN is due to the loss of the SMN1 gene and inefficient splicing of the SMN2 gene caused by a C>T mutation in exon 7. Global analysis of the severe SMNΔ7 SMA mouse model revealed altered splicing and increased levels of the hypoxia-inducible transcript, Hif3alpha, at late stages of disease progression. Severe SMA patients also develop respiratory deficiency during disease progression. We sought to evaluate whether hypoxia was capable of altering SMN2 exon 7 splicing and whether increased oxygenation could modulate disease in a severe SMA mouse model. Hypoxia treatment in cell culture increased SMN2 exon 7 skipping and reduced SMN protein levels. Concordantly, the treatment of SMNΔ7 mice with hyperoxia treatment increased the inclusion of SMN2 exon 7 in skeletal muscles and resulted in improved motor function. Transfection splicing assays of SMN minigenes under hypoxia revealed that hypoxia-induced skipping is dependent on poor exon definition due to the SMN2 C>T mutation and suboptimal 5' splice site. Hypoxia treatment in cell culture led to increased hnRNP A1 and Sam68 levels. Mutation of hnRNP A1-binding sites prevented hypoxia-induced skipping of SMN exon 7 and was found to bind both hnRNP A1 and Sam68. These results implicate hypoxic stress as a modulator of SMN2 exon 7 splicing in disease progression and a coordinated regulation by hnRNP A1 and Sam68 as modifiers of hypoxia-induced skipping of SMN exon 7.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22763238      PMCID: PMC3441125          DOI: 10.1093/hmg/dds263

Source DB:  PubMed          Journal:  Hum Mol Genet        ISSN: 0964-6906            Impact factor:   6.150


  53 in total

1.  Mice deficient in Mkp-1 develop more severe pulmonary hypertension and greater lung protein levels of arginase in response to chronic hypoxia.

Authors:  Yi Jin; Thomas J Calvert; Bernadette Chen; Louis G Chicoine; Mandar Joshi; John Anthony Bauer; Yusen Liu; Leif D Nelin
Journal:  Am J Physiol Heart Circ Physiol       Date:  2010-02-19       Impact factor: 4.733

2.  Identification of proximal spinal muscular atrophy carriers and patients by analysis of SMNT and SMNC gene copy number.

Authors:  P E McAndrew; D W Parsons; L R Simard; C Rochette; P N Ray; J R Mendell; T W Prior; A H Burghes
Journal:  Am J Hum Genet       Date:  1997-06       Impact factor: 11.025

3.  Nocturnal hypoxaemia and hypercapnia in children with neuromuscular disorders.

Authors:  Chiara Bersanini; Sonia Khirani; Adriana Ramirez; Frédéric Lofaso; Guillaume Aubertin; Nicole Beydon; Michèle Mayer; Kim Maincent; Michèle Boulé; Brigitte Fauroux
Journal:  Eur Respir J       Date:  2011-12-01       Impact factor: 16.671

4.  The splicing regulator Sam68 binds to a novel exonic splicing silencer and functions in SMN2 alternative splicing in spinal muscular atrophy.

Authors:  Simona Pedrotti; Pamela Bielli; Maria Paola Paronetto; Fabiola Ciccosanti; Gian Maria Fimia; Stefan Stamm; James L Manley; Claudio Sette
Journal:  EMBO J       Date:  2010-02-25       Impact factor: 11.598

5.  SMN deficiency disrupts brain development in a mouse model of severe spinal muscular atrophy.

Authors:  Thomas M Wishart; Jack P-W Huang; Lyndsay M Murray; Douglas J Lamont; Chantal A Mutsaers; Jenny Ross; Pascal Geldsetzer; Olaf Ansorge; Kevin Talbot; Simon H Parson; Thomas H Gillingwater
Journal:  Hum Mol Genet       Date:  2010-08-12       Impact factor: 6.150

6.  Sam68 relocalization into stress granules in response to oxidative stress through complexing with TIA-1.

Authors:  Jorge Henao-Mejia; Johnny J He
Journal:  Exp Cell Res       Date:  2009-07-14       Impact factor: 3.905

7.  Emerging treatment options for spinal muscular atrophy.

Authors:  Barrington G Burnett; Thomas O Crawford; Charlotte J Sumner
Journal:  Curr Treat Options Neurol       Date:  2009-03       Impact factor: 3.598

8.  hnRNP A1 functions with specificity in repression of SMN2 exon 7 splicing.

Authors:  Tsuyoshi Kashima; Nishta Rao; Charles J David; James L Manley
Journal:  Hum Mol Genet       Date:  2007-09-19       Impact factor: 6.150

9.  Antisense masking of an hnRNP A1/A2 intronic splicing silencer corrects SMN2 splicing in transgenic mice.

Authors:  Yimin Hua; Timothy A Vickers; Hazeem L Okunola; C Frank Bennett; Adrian R Krainer
Journal:  Am J Hum Genet       Date:  2008-03-27       Impact factor: 11.025

10.  Peripheral SMN restoration is essential for long-term rescue of a severe spinal muscular atrophy mouse model.

Authors:  Yimin Hua; Kentaro Sahashi; Frank Rigo; Gene Hung; Guy Horev; C Frank Bennett; Adrian R Krainer
Journal:  Nature       Date:  2011-10-05       Impact factor: 49.962

View more
  15 in total

Review 1.  Hypoxia-induced alternative splicing in human diseases: the pledge, the turn, and the prestige.

Authors:  Subhashis Natua; Cheemala Ashok; Sanjeev Shukla
Journal:  Cell Mol Life Sci       Date:  2021-01-02       Impact factor: 9.261

2.  Heat increases full-length SMN splicing: promise for splice-augmenting therapies for SMA.

Authors:  Catherine E Dominguez; David Cunningham; Akila S Venkataramany; Dawn S Chandler
Journal:  Hum Genet       Date:  2022-01-28       Impact factor: 5.881

Review 3.  Mechanistic principles of antisense targets for the treatment of spinal muscular atrophy.

Authors:  Natalia N Singh; Brian M Lee; Christine J DiDonato; Ravindra N Singh
Journal:  Future Med Chem       Date:  2015-09-18       Impact factor: 3.808

Review 4.  SMN regulation in SMA and in response to stress: new paradigms and therapeutic possibilities.

Authors:  Catherine E Dominguez; David Cunningham; Dawn S Chandler
Journal:  Hum Genet       Date:  2017-08-29       Impact factor: 4.132

Review 5.  Spinal muscular atrophy: Broad disease spectrum and sex-specific phenotypes.

Authors:  Natalia N Singh; Shaine Hoffman; Prabhakara P Reddi; Ravindra N Singh
Journal:  Biochim Biophys Acta Mol Basis Dis       Date:  2021-01-05       Impact factor: 5.187

Review 6.  Revisiting the role of mitochondria in spinal muscular atrophy.

Authors:  Rachel James; Helena Chaytow; Leire M Ledahawsky; Thomas H Gillingwater
Journal:  Cell Mol Life Sci       Date:  2021-04-05       Impact factor: 9.261

Review 7.  Invited review: decoding the pathophysiological mechanisms that underlie RNA dysregulation in neurodegenerative disorders: a review of the current state of the art.

Authors:  Matthew J Walsh; Johnathan Cooper-Knock; Jennifer E Dodd; Matthew J Stopford; Simeon R Mihaylov; Janine Kirby; Pamela J Shaw; Guillaume M Hautbergue
Journal:  Neuropathol Appl Neurobiol       Date:  2015-02       Impact factor: 8.090

Review 8.  Emerging therapies and challenges in spinal muscular atrophy.

Authors:  Michelle A Farrar; Susanna B Park; Steve Vucic; Kate A Carey; Bradley J Turner; Thomas H Gillingwater; Kathryn J Swoboda; Matthew C Kiernan
Journal:  Ann Neurol       Date:  2017-02-17       Impact factor: 10.422

9.  Pathological impact of SMN2 mis-splicing in adult SMA mice.

Authors:  Kentaro Sahashi; Karen K Y Ling; Yimin Hua; John Erby Wilkinson; Tomoki Nomakuchi; Frank Rigo; Gene Hung; David Xu; Ya-Ping Jiang; Richard Z Lin; Chien-Ping Ko; C Frank Bennett; Adrian R Krainer
Journal:  EMBO Mol Med       Date:  2013-09-09       Impact factor: 12.137

10.  Hypoxia leads to significant changes in alternative splicing and elevated expression of CLK splice factor kinases in PC3 prostate cancer cells.

Authors:  Elizabeth Bowler; Sean Porazinski; Simon Uzor; Philippe Thibault; Mathieu Durand; Elvy Lapointe; Kasper M A Rouschop; John Hancock; Ian Wilson; Michael Ladomery
Journal:  BMC Cancer       Date:  2018-04-02       Impact factor: 4.430

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.